Thymic carcinoma medical therapy

	Thymic Carcinoma Microchapters
Home
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Thymic carcinoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiograph and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Future or Investigational Therapies
Case Studies
Case #1
Thymic carcinoma medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Google Images
American Roentgen Ray Society Images of Thymic carcinoma medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Thymic carcinoma medical therapy
CDC on Thymic carcinoma medical therapy
Thymic carcinoma medical therapy in the news
Blogs on Thymic carcinoma medical therapy
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Thymic carcinoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]

Overview

The predominant therapy for thymic carcinoma is surgical resection. Adjunctive cisplatin-based chemotherapy may be required.^[1]

Medical treatment options for thymic carcinoma include the following:^[1]

CAP regimen (cyclophosphamide, doxorubicin, cisplatin): this is the first-line regimen
Sunitinib^[2]
Gemcitabine
Docetaxel
Checkpoint inhibitors
Radiation

Multimodality approach, such as:

↑ ^1.0 ^1.1 National Cancer Institute. General Information About Thymoma and Thymic Carcinoma Treatment. http://www.cancer.gov/types/thymoma/hp/thymoma-treatment-pdq. Accessed on 22nd December, 2015.
↑ Thomas A, Rajan A, Berman A, Tomita Y, Brzezniak C, Lee MJ; et al. (2015). "Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial". Lancet Oncol. 16 (2): 177–86. doi:10.1016/S1470-2045(14)71181-7. PMC 4401497. PMID 25592632.